An analysis of EMERALD and LEAP trial criteria against real-world HCC cases reveals that a majority of complex patients (e.g., multifocal, large tumors) who could most benefit from combination therapies were ineligible, cautioning clinicians against broad application of trial results.
Positive Phase 3 trials in intermediate HCC met their primary Progression-Free Survival (PFS) endpoints. Criticizing them for not showing an overall survival benefit—an endpoint they weren't powered for—is a retrospective invalidation that risks discarding clinically meaningful advances.
While median survival improvements in advanced HCC are notable, the truly revolutionary impact of immunotherapy is the creation of a long-term survival "tail" on the Kaplan-Meier curve. Clinicians now manage patients for years, a reality that was nonexistent in the pre-IO era.
Immunotherapy is now inducing complete responses in a small subset of advanced HCC patients. This success presents a novel challenge, as there is no data to guide decisions on treatment duration, forcing difficult discussions about stopping therapy in patients who may be cured.
The systemic anti-tumor response from local therapy (abscopal effect) is so rare in HCC that it's compared to a mythical creature. Despite its rarity, the pursuit of this phenomenon continues to drive the design of combination immunotherapy and loco-regional therapy trials.
The TOURMALINE study confirmed that pairing the checkpoint inhibitor Durvalumab with various gemcitabine-based chemo combinations (not just cisplatin) is safe and effective in biliary tract cancer. This provides crucial real-world evidence supporting clinical flexibility beyond the rigid protocols of pivotal trials.